Oncologists Likely to Get Small Medicare Increases

Publication
Article
OncologyONCOLOGY Vol 13 No 9
Volume 13
Issue 9

Anyone who remembers the bruising political battle in 1997-1998over how Medicare would develop “resource-based” practice expenses can breathe a sign of relief over what is likely to be the painless shift to resource-based malpractice

Anyone who remembers the bruising political battle in 1997-1998over how Medicare would develop “resource-based” practice expenses can breathe a sign of relief over what is likely to be the painless shift to resource-based malpractice expenses. Medicare will work them into its payment formula starting January 1, 2000. That formula takes into account three relative value units (RVUs): for work (accounts for 54.5% of the total payment), practice expense (42.3%), and malpractice expense (3.2%). These three RVUs are added together and then multiplied by a conversion factor of $34.73. The fact that malpractice expenses are such a small part of the formula explains why payment for hematology/oncology codes will increase only 0.3 in 2000, which is fairly typical for most specialties. Medicare also wants to refine some of its practice expense RVUs. That would give hematology/oncology a 1% increase in 2002 over what payments would have been otherwise.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content